SCHEMBL2461467

SCHEMBL2461467

NCC#C[N+]12C=CN=CC1=C(C1=CC=C1)N=C2c1cccc(OCc2ccccc2)c1

nearest known ligand 0.34

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAOB P27338 3/20 0.33
MRGPRX4 Q96LA9 1/20 0.33
PIK3CD O00329 1/20 0.33
PIK3CA P42336 1/20 0.33
PIK3CB P42338 1/20 0.33
PIK3CG P48736 1/20 0.33
PRKDC P78527 1/20 0.33
IGF1R P08069 3/20 0.32
NR1H2 P55055 1/20 0.32
NR4A2 P43354 2/20 0.32
BACE1 P56817 1/20 0.32
DHFR P00374 1/20 0.32
NR1H4 Q96RI1 1/20 0.31
SPHK2 Q9NRA0 1/20 0.31
PIM1 P11309 1/20 0.31
PIM2 Q9P1W9 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2460200 0.86 MAOB (0.37) MAOBMRGPRX4PIK3CDPIK3CAPIK3CB
SCHEMBL2457047 0.83 MAOB (0.34) MAOBMRGPRX4PIK3CDPIK3CAPIK3CB
SCHEMBL2458350 0.83 MRGPRX4 (0.38) MAOBMRGPRX4NR1H2NR4A2BACE1
SCHEMBL2460741 0.82 SMPD1 (0.36) MAOBMRGPRX4PIK3CDPIK3CAPIK3CB
SCHEMBL2460590 0.82 IGF1R (0.35) MAOBMRGPRX4PIK3CDPIK3CAPIK3CB
SCHEMBL2464139 0.81 NR1H2 (0.35) MAOBMRGPRX4PIK3CDPIK3CAPIK3CB
SCHEMBL2463035 0.80 BCHE (0.37) MAOBMRGPRX4NR1H2NR4A2NR1H4
SCHEMBL2460646 0.80 NR1H4 (0.37) MAOBMRGPRX4NR1H2NR4A2NR1H4
SCHEMBL2463246 0.80 BCHE (0.37) MAOBMRGPRX4NR1H2NR4A2NR1H4
SCHEMBL2456898 0.80 NOS1 (0.35) MAOBMRGPRX4NR4A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1675860-B1 IMIDAZO[1,5-A]PYRAZINES AS TYROSINE KINASE INHIBITORS OSI PHARM INC (US) 2011-09-21 EP disclosed
US-20090181940-A1 Imidazopyrazine Tyrosine Kinase Inhibitors OSI PHARMACEUTICALS, INC. 2009-07-16 US disclosed
US-7459554-B2 Imidazopyrazine tyrosine kinase inhibitors OSI PHARMACEUTICALS, INC. (US) 2008-12-02 US disclosed
US-20080227788-A9 IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS BECK PATRICIA A 2008-09-18 US disclosed
US-20060084654-A1 Imidazopyrazine tyrosine kinase inhibitors ACERTA PHARMA B.V. (NL) 2006-04-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080227788-A9 IMIDAZOPYRAZINE TYROSINE KINASE INHIBITORS IGF1R, IRS1, IGFBP1 MAOB 1546/4885MRGPRX4 1767/4885PIK3CD 636/4885
US-20060084654-A1 Imidazopyrazine tyrosine kinase inhibitors IGF1R, IRS1, IGFBP1 MAOB 1546/4885MRGPRX4 1767/4885PIK3CD 636/4885
US-20090181940-A1 Imidazopyrazine Tyrosine Kinase Inhibitors IGF1R, IRS1, IGFBP1 MAOB 1546/4885MRGPRX4 1767/4885PIK3CD 636/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.